AccScience Publishing / IMO / Online First / DOI: 10.36922/IMO025260027
Submit to IMO
Cite this article
6
Download
41
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

In silico evaluation of ursodeoxycholic acid from Jania rubens and its analogs as potential anti-Alzheimer’s agents

Oluwafemi S. Aina1,2* ,  Owoyemi W. Elegbeleye3 ,  Nafisat O. Babamusa1 ,  Mujeeb O. Rofiu1 ,  Kafayat A. Owoseni-Fagbenro1 ,  Olubusayo F. Semire1 ,  Olasupo A. Idris1 ,  Luqman A. Adams1 ,  Oluwole B. Familoni1
Show Less
1 Department of Chemistry, Faculty of Science, University of Lagos, Lagos, Nigeria
2 Department of Biological Sciences, Faculty of Basic Medical and Applied Sciences, Trinity University, Lagos, Nigeria
3 Department of Marine Sciences, Faculty of Science, University of Lagos, Lagos, Nigeria
IMO, 025260027 https://doi.org/10.36922/IMO025260027
Received: 24 June 2025 | Revised: 25 August 2025 | Accepted: 2 September 2025 | Published online: 14 October 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Alzheimer’s disease (AD), one of the neurodegenerative disorders, is marked by the gradual degeneration of nerve cells in the brain or peripheral nervous system, along with abnormal protein aggregation. While significant efforts have been made to manage AD, a dearth of data remains on candidate phytochemicals and analogs in its treatment. Herein, we present alkaloids derived from the marine algae Jania rubens as potential inhibitors of human acetylcholinesterase (AChE) relevant to AD therapy. Using in silico tools, such as Protox II and SwissADME, 40 isolates were screened for toxicity and absorption, distribution, metabolism, and excretion properties. Molecular docking simulations were performed using PyRx 0.8, AutoDock Vina Wizard, and Discovery Studio 2020. A 50-nanosecond molecular dynamics simulation was performed using the Groningen Molecular Simulation in the LINUX environment and bio-organic molecules force field simulation (CHARMM 36). Ursodeoxycholic acid (AL20), an isolate from J. rubens, exhibited strong inhibitory activity against AChE with a binding energy of −8.5 kcal/mol, surpassing standard anti-Alzheimer drugs donepezil (−8.3 kcal/mol), galantamine (−7.7 kcal/mol), and rivastigmine (−6.4 kcal/mol). However, in silico data revealed a 73% probability of hepatotoxicity for AL20. Thereafter, seven derivatives (AL20A–G) were designed to improve properties for drug likeness. The amide analog, AL20E, showed superior inhibitory activity (−9.0 kcal/mol) and non-toxicity compared to AL20 and the standard drugs. This derivative also demonstrated strong interactions with the AChE enzyme, forming three hydrogen bonds with amino acid residues Pro290, Ser293, and Leu289. The brain or intestinal estimated permeation model predicted favorable gastrointestinal absorption and blood–brain barrier penetration for AL20E, indicating its potential as a central nervous system-active drug. Density functional theory and molecular dynamics analyses confirmed the chemical stability of AL20E, making it a promising candidate for the development of an anti-Alzheimer drug. This study highlights AL20E ([4R]-4-[{3S,7S,8R,9S,10S,13R,14S,17R}-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H cyclopenta{a}phenanthren-17-yl]pentanamide) as a non-toxic, AchE inhibitor with enhanced drug-likeness. This study thereby presents AL20E for consideration as a lead compound in the development of novel Alzheimer’s therapeutics.

Keywords
Jania rubens
In silico analysis
Ursodeoxycholic acid
Acetylcholinesterase
Anti-Alzheimer drug
Funding
None.
Conflict of interest
The authors declare that they have no competing of interests.
References
  1. Li B, He DJ, Li XJ, Guo XY. Modeling neurodegenerative diseases using non-human primates: Advances and challenges. Ageing Neurodegener Dis. 2022;2(3):12. doi: 10.20517/and.2022.14

 

  1. Kumar A, Sudevan ST, Nair AS, et al. Current and future nano-carrier-based approaches in the treatment of Alzheimer’s disease. Brain Sci. 2023;13(2):213. doi: 10.3390/brainsci13020213

 

  1. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer’s disease? CNS Neurosci Ther. 2010;16(4):235-245. doi: 10.1111/j.1755-5949.2010.00175.x

 

  1. Joo SS, Won TJ, Lee DI. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch Pharm Res. 2004;27(9):954-960. doi: 10.1007/bf02975850

 

  1. Giacobini E. Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacol Res. 2004;50(4):433-440. doi: 10.1016/j.phrs.2003.11.017

 

  1. Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1996;277(2):728-738.

 

  1. Cortez LM, Campeau J, Norman G, et al. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. J Virol. 2015;89(15): 7660-7672. doi: 10.1128/JVI.01165-15

 

  1. Silva RF, Rodrigues CM, Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid. J Hepatol. 2001;34(3):402-408. doi: 10.1016/S0168-8278(01)00015-0

 

  1. Guven KC, Percot A, Sezik E. Alkaloids in marine algae. Mar Drugs. 2010;8(2):269-284. doi: 10.3390/md8020269

 

  1. Souza CR, Bezerra WP, Souto JT. Marine alkaloids with anti-inflammatory activity: Current knowledge and future perspectives. Mar Drugs. 2020;18(3):147. doi: 10.3390/md18030147

 

  1. El-Din SMM, El-Ahwany AM. Bioactivity and phytochemical constituents of marine red seaweeds (Jania rubens, Corallina mediterranea and Pterocladia capillacea). J Taibah Univ Sci. 2016;10(4):471–484. doi: 10.1016/j.jtusci.2015.06.004

 

  1. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi: 10.1002/jcc.21334

 

  1. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19(14):1639-1662. doi: 10.1002/(sici)1096-987x(19981115)19:14%3c1639:aid-jcc10%3e3.0.co;2-b

 

  1. Lipinski B, Herzog H, Kops ER, Oberschelp W, Müller- Gärtner HW. Expectation maximization reconstruction of positron emission tomography images using anatomical magnetic resonance information. IEEE Trans Med Imaging. 1997;16(2):129-136. doi: 10.1109/42.563658

 

  1. Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, Revision B.01. Connecticut: Gaussian Inc., 2010. Available from: https://cir.nii.ac.jp/crid/1370298757422456580 [Last accessed on 2023 Mar 12].

 

  1. Rivero P, Moreira IDP, Illas F, Scuseria GE. Reliability of range-separated hybrid functionals for describing magnetic coupling in molecular systems. J Chem Phys. 2008;129(18):184110. doi: 10.1063/1.3006419

 

  1. Bielecki J, Lipiec E. Basis set dependence using DFT/B3LYP calculations to model the Raman spectrum of thymine. J Bioinform Comput Biol. 2016;14(1):1650002. doi: 10.1142/s0219720016500025

 

  1. García-Valverde M, Cordero NA, De la Cal ES. Gaussview (R) as a tool for learning organic chemistry. In: Edulearn15: 7th International Conference on Education and New Learning Technologies; 2015. p. 4366-4370.

 

  1. Chitra L, Kumar CR, Basha HM, Ponne S, Boopathy R. Interaction of metal chelators with different molecular forms of acetylcholinesterase and its significance in Alzheimer’s disease treatment. Proteins. 2013;81(7):1179-1191. doi: 10.1002/prot.24267

 

  1. Murugesan B, Somasundram B, Samykannu G, et al. Exploring lichen-derived compounds as potential anti-cervical cancer agents: An DFT and MD simulation analysis. In-Silico Pharmacol. 2025;13(2):114. doi: 10.1007/s40203-025-00380-y

 

  1. Daina A, Zoete V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117-1121. doi: 10.1002/cmdc.201600182

 

  1. Daina A, Michielin O, Zoete V. iLOGP: A simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model. 2014;54(12):3284-3301. doi: 10.1021/ci500467k

 

  1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1):3-26. doi: 10.1016/S0169-409X(00)00129-0

 

  1. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. Neurotherapeutics. 2005;2(1):3-14. doi: 10.1602/neurorx.2.1.3

 

  1. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: Methods and studies. Fundam Clin Pharmacol. 1999;13(2):154-168. doi: 10.1111/j.1472-8206.1999.tb00334.x

 

  1. Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018;214:118-123. doi: 10.1016/j.lfs.2018.10.048

 

  1. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet. 2003;42(1):59-98. doi: 10.2165/00003088-200342010-00003

 

  1. Dong J, Qin Z, Zhang WD, et al. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist Update. 2020;49:100681. doi: 10.1016/j.drup.2020.100681

 

  1. Aina OS, Rofiu MO, Oloba-Whenu OA, Olasupo IA, Adams LA, Familoni OB. Drug design and in-silico study of 2-alkoxylated quinoline-3-carbaldehyde compounds: Inhibitors of Mycobacterium tuberculosis. Sci Afr. 2024;23:e01985. doi: 10.1016/j.sciaf.2023.e01985

 

  1. Geerlings P, Chamorro E, Chattaraj PK, et al. Conceptual density functional theory: Status, prospects, issues. Theor Chem Acc. 2020;139(2):36. doi: 10.1007/s00214-020-2546-7

 

  1. Pal R, Chattaraj PK. Electrophilicity index revisited. J Comput Chem. 2023;44(3):278-297. doi: 10.1002/jcc.26886

 

  1. Galabov B, Ilieva S, Koleva G, Allen WD, Schaefer HF 3rd, Schleyer PVR. Structure-reactivity relationships for aromatic molecules: Electrostatic potentials at nuclei and electrophile affinity indices. Wiley Interdiscip Rev Comput Mol Sci. 2013;3(1):37-55. doi: 10.1002/wcms.1112

 

  1. Dos Santos MAB, De Oliveira LFS, De Figueiredo AF, et al. Molecular electrostatic potential and chemometric techniques as tools to design bioactive compounds. In: Cheminformatics and its Applications. London: IntechOpen; 2019. doi: 10.5772/intechopen.89113

 

  1. Berendsen HJC, Van der Spoel D, Van Drunen R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun. 1995;91(1-3):43-56. doi: 10.1016/0010-4655(95)00042-e

 

  1. Shintani EY, Uchida KM. Donepezil: An anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm. 1997;54(24):2805-2810. doi: 10.1093/ajhp/54.24.2805
Next article in this issue
Share
Back to top
Innovative Medicines & Omics, Electronic ISSN: 3060-8740 Print ISSN: 3060-8910, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept